BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15964291)

  • 1. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
    Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
    Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
    Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Sivin I; Tsong YY; Fraser IS
    Contraception; 2005 Jul; 72(1):46-52. PubMed ID: 15964292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.
    Sivin I; Mishell DR; Alvarez F; Brache V; Elomaa K; Lähteenmäki P; Massai R; Miranda P; Croxatto H; Dean C; Small M; Nash H; Jackanicz TM
    Contraception; 2005 Feb; 71(2):122-9. PubMed ID: 15707562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
    Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
    Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol.
    Tiedeken M; Westhoff CL; Cohen A; Cremers S; Sitruk-Ware R; Blithe DL;
    Contraception; 2019 Jun; 99(6):329-334. PubMed ID: 30871934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
    Victor A; Lithell H; Selinus I; Vessby B
    Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women.
    Brache V; Merkatz R; Kumar N; Jesam C; Sussman H; Hoskin E; Roberts K; Alami M; Taylor D; Jorge A; Croxatto H; Lorange E; Mishell DR; Sitruk-Ware R
    Contraception; 2015 Oct; 92(4):289-97. PubMed ID: 26032952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
    Simmons KB; Kumar N; Plagianos M; Roberts K; Hoskin E; Han L; Alami M; Creasy G; Variano B; Merkatz R
    Contraception; 2018 Mar; 97(3):270-276. PubMed ID: 29097225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete and robust ovulation inhibition with NuvaRing.
    Killick S
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.
    Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R
    Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive.
    Fraser IS; Weisberg E; Kumar N; Kumar S; Humberstone AJ; McCrossin L; Shaw D; Tsong YY; Sitruk-Ware R
    Contraception; 2007 Dec; 76(6):432-8. PubMed ID: 18061700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
    Brache V; Mishell DR; Lahteenmaki P; Alvarez F; Elomaa K; Jackanicz T; Faundes A
    Contraception; 2001 May; 63(5):257-61. PubMed ID: 11448466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
    Jensen JT; Edelman AB; Chen BA; Archer DF; Barnhart KT; Thomas MA; Burke AE; Westhoff CL; Wan LS; Sitruk-Ware R; Kumar N; Variano B; Blithe DL
    Contraception; 2018 May; 97(5):422-427. PubMed ID: 29409834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
    Rad M; Kluft C; Ménard J; Burggraaf J; de Kam ML; Meijer P; Sivin I; Sitruk-Ware RL
    Am J Obstet Gynecol; 2006 Jul; 195(1):72-7. PubMed ID: 16545330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring.
    Stifani BM; Plagianos M; Vieira CS; Merkatz RB
    Contraception; 2018 May; 97(5):415-421. PubMed ID: 29269252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.